Unfractionated Heparin Drug Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025
- Transparency Market Research
- February 2034
- Healthcare IT
- 0 pages
Unfractionated heparin drug is an anticoagulant drug. It is a high
molecular weight heparin drug ranging from 3,000 Da to 30,000 Da. The
unfractionated heparin drug is a heterogeneous mixture of linear
polysaccharide chains with variable biological activity and molecular
weight, and a pentasaccharide that has minimal active fragment.
Unfractionated heparin is the most primitive form of heparin and has major
applications in kidney dialysis and heart, and lung oxygenation that
includes the treatment and prevention of pulmonary embolism, deep vein
thrombosis, post-operative thrombosis, certain types of coronary artery
syndrome, particularly unstable angina, in thrombotic stroke, and
Unfractionated heparin binds reversibly with anti-thrombin III (ATIII). This enhances the rate at which ATIII inactivates coagulation enzymes such as thrombin factor Xa and factor IIa. Unfractionated heparin is primarily utilized in hospitals for the prevention and treatment of thrombosis. In 2008, numerous consignments of heparin imported to the U.S. from China were contaminated with oversulfated chondroitin sulfate. This led to the establishment of stringent production and purification guidelines worldwide. According to the University of Wisconsin Hospitals and Clinics Authority, unfractionated heparin is a better option as compared to low molecular weight heparin as the former is used intravenously for the treatment of anticoagulation. The adjustment of infusion rate and monitoring is required for the immediate onset of the intravenous unfractionated heparin.
Unfractionated heparin is eliminated through the liver. It gets eliminated faster due to its high molecular weight, and it is highly preferred in dialysis. This is a driving factor for the growth of the global unfractionated heparin drug market. Several studies have confirmed that unfractionated heparin has more specificity than low molecular weight heparin, and its effect can be reversed by using protamine sulfate. This advantage over low molecular weight heparin has led unfractionated heparin to sustain in the market. According to the World Health Organization (WHO), there is a high risk for the development of venous thromboembolism which is caused due to prolonged traveling in passengers via automobile, bus, train, or airplane, for more than four hours. This is one of the driving factors of the market growth. However, increasing use of anticoagulants in dialysis as an alternative has decreased the usage of unfractionated heparin, which is likely to restraint the growth of the market for unfractionated heparin drug during the forecast period.
The global unfractionated heparin drug market has been categorized based on type of packaging, dosing type of body weight, type of strength, end-user, and region. In terms of type of packaging, the market is divided into ampoules, multi-dose vials, single-dose vials, and prefilled/preloaded syringes. On the basis of dosing type of body weight, the market is segmented into morbidly obese patients, obese patients, and non-obese patients. In terms of type of strength, the market is segmented into 2,000, 5,000, 10,000, 20,000, and above 20,000 billion units. In terms of end-user, the market is categorized into hospitals, nursing homes and private clinics, assisted living facilities (ALFs) & long term care institutions, and home health care.
Geographically, the global unfractionated heparin drug market is distributed over North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to hold a large share of the global market during the forecast period owing to technological developments. The market in Asia Pacific is anticipated to grow during the forecast period owing to increasing government initiatives and growing awareness.
Key players operating in the global unfractionated heparin drug market include Dr. Reddy’s Laboratories Ltd., Fresenius Kabi AG, LEO Pharma A/S, Pfizer, Inc., and Sanofi S.A.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Have query on this report?Make an Enquiry
The team was the biggest help to us. Not only were we provided with customized solutions but also we were guided through the most complicated situations. The information was on-point yet comprehensive. The experience was absolutely satisfying and helped us turn many challenges into opportunities.
Ours is a startup with a unique set of challenges and we were therefore hesitant but the team totally put us at ease with their knowledge and expertise. Our business and its challenges were understood perfectly and help was extended accordingly. The tailor made approach really helped us gain the most informative insights.
The report repository is absolutely impressive –updated and exhaustive in terms of markets covered and information provides. Besides, with the support extended to us by the team, we could reduce costs as well as move to sustainable growth. This really helped us tap into new opportunities. Happy to have gone ahead with ResearchMos.us.
We have had a long term engagement with ResearchMoz.us and never have we felt that the work done and help extended were below flawless. The report repository is one of the best one can hope to tap into. Recently, our partner businesses opted for consultancy services and they are all thrilled with the outcome.
Insights from reports helped us improve our profit margins significantly. Most of the knowledge we needed on the market were provided to us on a granular basis. From trends, and drivers to competitive analysis, the information was not just crisp but also insightful. That helped us chart a robust growth strategy and as of now we are happy to state that we are reaping big benefits.
More from Healthcare IT
Healthcare ITGlobal mHealth Market Research Report 2016
Pharmaceuticals and HealthcareGlobal Bionic Ears Market Professional Survey Report 2017
Pharmaceuticals and HealthcareNeuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Pharmaceuticals and HealthcareHepatitis Drug Development Pipeline Review, 2017